Discover
ETNB
89bio, Inc.
14.84
19 x 14.82
1 x 14.86
bid
ask
+
14.84
0.00%
07:00 PM
| Ytd | 89.77% | |
| 1y | 85.73% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -5.17 |
| Beta | 1.26 | Short Ratio | 0.74 | Inst. Own | 103.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 30.38 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-06 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-07 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-05-01 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-02-27 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-11-07 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-08-05 | 2024-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-09-19 | Raymond James | Downgrade | Outperform | Market Perform |
| 2025-09-19 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| 2025-09-19 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2025-08-25 | B of A Securities | Upgrade | Buy | Buy |
| 2025-08-08 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-03-14 | Goldman Sachs | Upgrade | Neutral |
Profile
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-10-29 | LE-NGUYEN QUOC | Chief Operating Officer | 0.00 | Stock Award(Grant) |
| 2025-01-30 | MANSBACH HARRY H | Officer | 323.70K | Stock Award(Grant) |
| 2025-10-21 | MARTINS RYAN | Chief Financial Officer | 339.30K | Conversion of Exercise of derivative security |
| 2025-01-21 | MCWHERTER CHARLES A | Director | 25.00K | Purchase |
| 2025-01-30 | PALEKAR ROHAN | Chief Executive Officer | 873.64K | Stock Award(Grant) |
| 2025-01-29 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | Janus Henderson Group PLC | 20.79M | 308.50M | 14.02% |
| 2025-06-29 | RA Capital Management, L.P. | 19.89M | 295.16M | 13.41% |
| 2025-06-29 | Suvretta Capital Management, LLC | 14.21M | 210.88M | 9.58% |
| 2025-06-29 | Blackrock Inc. | 10.57M | 156.85M | 7.13% |
| 2025-06-29 | Deep Track Capital, Lp | 9.50M | 140.98M | 6.41% |
| 2025-06-29 | Vanguard Group Inc | 8.24M | 122.31M | 5.56% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.81M | 71.32M | 3.24% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 ETF | 3.07M | 45.50M | 2.07% |
| 2025-06-29 | JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 2.92M | 43.38M | 1.97% |
| 2025-09-29 | SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | 2.55M | 37.88M | 1.72% |
| 2025-06-29 | JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 2.35M | 34.80M | 1.58% |
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.01M | 29.80M | 1.35% |